Prior Specific Biologic Use as a Potential Risk Factor for Administration-related Reactions to Ixekizumab after Excipient Modification: A Single-centre Retrospective Study
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0461Keywords:
psoriasis, Biological Therapy, adverse effects, InjectionsDownloads
References
Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375: 345–356. DOI: https://doi.org/10.1056/NEJMoa1512711
Chabra S, Gill BJ, Gallo G, Zhu D, Pitou C, Payne CD, et al. Ixekizumab citrate-free formulation: results from two clinical trials. Adv Ther 2022; 39: 2862–2872. DOI: https://doi.org/10.1007/s12325-022-02126-0
Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315–1324. DOI: https://doi.org/10.1111/j.1572-0241.2003.07457.x
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 2013; 48: 452–458. DOI: https://doi.org/10.1038/bmt.2012.244
Shear NH, Paul C, Blauvelt A, Gooderham M, Leonardi C, Reich K, et al. Safety and tolerability of ixekizumab: integrated analysis of injection-site reactions from 11 clinical trials. J Drugs Dermatol 2018; 17: 200–206.
Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol 2023; 89: 1149–1158. DOI: https://doi.org/10.1016/j.jaad.2023.07.1024
Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res 2016; 9: 39–50. DOI: https://doi.org/10.2147/JIR.S100940
Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodie. Front Immunol 2020; 11: 1951. DOI: https://doi.org/10.3389/fimmu.2020.01951
Chabra S, Birt J, Bolce R, Lisse J, Malatestinic WN, Zhu B, et al. Satisfaction with the injection experience of a new, citrate-free formulation of ixekizumab. Adv Ther 2024; 41: 1672–1684. DOI: https://doi.org/10.1007/s12325-024-02812-1
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
